The latest issue of Advances in Pulmonary Hypertension addresses Group 2 pulmonary hypertension, the most common cause of PH in the developed world. Caused by left heart disease, Group 2 PH has many diagnostic and therapeutic challenges.
This issue marks the first time Advances in PH features original research, “Effects of Face-to-Face Nursing Support on Optimal Adherence to Oral Titratable PAH Therapies.” Advances, the Pulmonary Hypertension Association’s quarterly peer-reviewed clinical journal, generally features articles submitted by invitation.
Volume 22, Issue 3, also includes these articles:
- Echocardiographic Evaluation of the Right Heart in Pulmonary Hypertension.
- Heart Failure with Preserved Ejection Fraction and the Diagnosis of Pulmonary Hypertension.
- Pediatric Pulmonary Hypertension in Left-Sided Heart Disease.
- Nonpharmacological Management of Heart Failure.
“This is clearly not a “one size fits all” disease,” say guest editors Marc A. Simon, MD, MS, and Richard A. Krasuski, MD. “In reading through this issue, a common theme reflected is how useful these articles will be to both experienced providers and all learners alike … We hope you enjoy and learn as much from this issue as we did in putting it together.”
Advances in Pulmonary Hypertension is available for free online. Register to be notified when future issues are published
